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Ras super-family small GTPases regulate diverse cellular processes such as vesicular transport and signal
transduction. Critical to these activities is the ability of these proteins to target to speciﬁc intracellular
membranes. To allow association with membranes Ras-related GTPases are post-translationally modiﬁed
by covalent attachment of prenyl groups to conserved cysteine residues at or near their C-terminus. Here
we used the HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase (HMGCR) inhibitor meva-
statin to develop a ‘prenylation block-and-release’ assay that allows membrane targeting of prenylated
proteins to be visualized in living cells. Using this assay we investigated the cytosol to membrane target-
ing of several small GTPases to compartments of the secretory and endocytic pathways. We found that all
Rabs tested were targeted directly to the membrane on which they reside at steady-state and not via an
intermediate location as reported for Ras and Rho proteins. However, we observed that the kinetics of
cytosol to membrane targeting differed for each Rab tested. Comparison of the mevastatin sensitivity
and kinetics of membrane targeting of Rab23, Rab23 prenylation motif mutants and H-Ras revealed that
these parameters are strongly dependent upon the prenyl transferase with Rab geranylgeranyl transfer-
ase substrates exhibiting higher sensitivity and requiring greater time to recover from mevastatin inhi-
bition than farnesyl transferase substrates. We propose that this assay is a useful tool to investigate the
kinetics, biological functions and the mechanisms of membrane targeting of prenylated proteins.
 2010 Elsevier Inc. Open access under CC BY license.1. Introduction
The post-translational modiﬁcation of peripheral membrane
proteins by lipids is a key mechanism in the regulation of protein
targeting and function in all eukaryotic cells. Prenylation is a lipidic
post-translational modiﬁcation involving the irreversible covalent
attachment of either farnesyl (15-carbon) or geranylgeranyl (20-
carbon) isoprenoids to conserved cysteine residues at or near the
C-terminus of numerous cellular proteins [1–3]. Prenylated pro-
teins in eukaryotes include nuclear lamins, Ras and Ras-related
small GTP-binding proteins, c subunit of trimeric G proteins, pro-
tein kinases, fungal mating factors and others [4–6]. Prenylation
is frequently associated to reversible post-translational modiﬁca-
tions or ligand binding events such as palmitoylation, phosphory-
lation or GTP-binding [5]. All members of the Ras super-family of
small GTPases with the exception of Ran, Rit and Sar1 are prenylat-thology, Faculty of Medicine
6, Al-Ain, UAE. Fax: +971 3
ity of Cambridge, Cambridge,
Y license.ed [4,6,7]. For Ras and Rho family GTPases, most of their members
are singly prenylated by either farnesyl transferase (FT) or geranyl-
geranyl transferase (GGT), respectively. The determinants allowing
recognition of substrate by FT and GGT have been studied exten-
sively [4]. The newly lipidated Ras and Rho proteins are then tar-
geted to the cytoplasmic face of the endoplasmic reticulum (ER)
where they undergo further modiﬁcation including removal of
the AAX tripeptide and methylation of the a-carboxyl group of
the newly exposed C-terminus prenyl-cysteine [6]. The processed
proteins are then trafﬁcked via classical or non-classical secretory
pathways to the plasma membrane and may be further modiﬁed
e.g. palmitoylated and phosphorylated. In contrast most members
of the Rab family have two C-terminus cysteine residues and once
in complex with chaperone Rab escort protein (REP-1/-2) may dou-
bly geranylgeranylated by Rab geranylgeranyl transferase (RGGT)
[4,8,9]. However, there are exceptions among the Rabs that contain
only one C-terminus cysteine e.g. Rab13 and 23 and are singly
prenylated by RGGT. Also within this subset some singly prenylat-
ed Rabs appear to have a bona ﬁde CAAX box e.g. Rab8 C-terminus
tetra-peptide CVLL, and may therefore be substrates for either
RGGT or GGT [4,8]. Nevertheless in vivo it is thought that all Rabs
are preferentially prenylated by RGGT [10–14]. This idea is based
on the observation that all Rabs contain ﬁve conserved sequence
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ognition by REP and consequently prenylation by RGGT [15]. After
prenylation Rab remains in complex with REP that plays a critical
role in targeting Rab to a speciﬁc membrane location by mecha-
nisms that are currently unclear [16].
The cholesterol lowering compounds known as statins were dis-
covered through isolation of microbial agents capable of disrupting
HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase
(HMGCR) activity. HMGCR catalyzes the committed step in choles-
terol biosynthesis [17], and is critical to production of ergosterol
and isoprenoids e.g. farnesyl (C15) and geranylgeranyl (C20) [18].
Mevastatinwas theﬁrst ofmany ‘statin’ compounds found to inhibit
HMGCR activity, and these compounds have since gained much
attention as cholesterol lowering drugs [19]. Statins also deplete
the cell of isoprenoids, essential for functionalityof proto-oncogenes
such as Ras and Rho, and as a result they have been the subject of re-
search into their potential application as anti-cancer therapeutics
[20,21]. Statins competitively inhibit the four-step deacylation of
HMG-CoA to mevalonate and CoA, with an inhibition constant (KI)
of 1 nM for statin:enzyme complexes and KM of 4 lM [22,23].
Here we describe the development and application of a prenyl-
ation block-and-release (PBAR) assay that exploits the ability of
mevastatin to reversibly block isoprenoid biosynthesis and allows
direct microscopic investigation of the mechanisms of membrane
targeting of prenylated GTPases.
2. Materials and methods
2.1. Reagents
Mevastatin and geranylgeraniol GGOH (Sigma) solutions were
prepared in cell culture media. Original stock concentration was
620 lM in ethanol for mevastatin and 500 lM in ethanol for gera-
nylgeraniol. Cycloheximide was used at 2 lg/ml. Antibodies direc-
ted against human transferrin receptor (Zymed) and Golgin-97
(Invitrogen) were used at 1:1000 dilution for immunoﬂuorescence.
2.2. Cell culture
HeLa cells were maintained in Dulbecco’s Modiﬁed Eagle Media
(DMEM:F12 (1:1) (Gibco) supplemented with 10% fetal bovine ser-
um (FBS), 2 mM glutamine, 100 U/ml penicillin G and 100 U/ml
streptomycin at 37 C with 10% CO2. AtT20 (a murine neuroendo-
crine pituitary tumor cell line) cells were cultured in DMEM:F12
2:1 with 15% FBS and equal concentrations of glutamine, penicillin
G and streptomycin. Immortal Rab27a null melanocyte cell line
melan-ash was maintained as described previously [11].
2.3. EGFP-GTPase fusion constructs
The construction of vectors pEGFP-Rab23, pEGFP-Rab1a, pEGFP-
Rab5, pEGFP-Rab27a and pEGFP-H-Ras were previously described
[10–13].
2.4. Transfection, immunoﬂuorescence, drug treatments and imaging
of cells
Transfection, ﬁxation and immunoﬂuorescence were performed
as previously described [11,13]. Drug treatments were initiated
90 min after addition of transfection complexes. This time-point
was chosen to begin administration of drugs as the cells are ex-
pected to have taken up the plasmid but are unlikely to have tar-
geted signiﬁcant levels of protein to the endomembrane system.
For live cell imaging cells were plated on glass bottomed 30 mm
dishes (Matek) and following wash-out of mevastatin were imaged
using the 488 nm laser-line of a Zeiss LSM-510 inverted confocalmicroscope with 100 1.4NA apochromat oil-immersion objective
lens. Images were contrast enhanced using Abode Photoshop CS
software and movies were assembled using ImageJ software.
3. Results
3.1. A mevastatin prenylation block-and-release (PBAR) assay to
monitor membrane targeting of prenylated small GTPases in living
cells
Our previous studies have investigated the mechanisms by
which newly synthesized Rab GTPases are prenylated and targeted
to speciﬁc intracellular compartments [10–12]. Here we demon-
strate the development of a prenylation block-and-release (PBAR)
assay that allows the recruitment of prenylated GTPases to speciﬁc
organelles to be monitored in real-time in living cells using a
microscope.
This assay relies upon the ability of mevastatin to act as a
reversible inhibitor of HMGCR and thereby block the production
of geranylgeranyl (GGPP) and farnesyl (FPP) pyrophosphates, the
precursors of the lipid moieties of the prenylation reactions. In turn
this blocks the prenylation of newly synthesized substrates of GGT,
RGGT and FT (e.g. Rho, Rab and Ras GTPases). Removal of the inhib-
itor releases this block by allowing GGPP and FPP production and
thus prenylation and membrane targeting of unprenylated sub-
strates. The process of membrane targeting from the cytosolic pool
of unprenylated protein to the membrane may then be observed
directly using ﬂuorescence microscopy.
In more detail, the protocol ﬁrst involves transfection of cells
with plasmid encoding an EGFP-GTPase fusion protein under the
control of the strong CMV promoter (Supplementary Fig. 1). This
allows expression of a large quantity of ﬂuorescently labeled pro-
tein. Shortly post-transfection (90 min) mevastatin is added to
cells to prevent prenylation and membrane targeting of newly syn-
thesized EGFP-GTPase thus a pool of unprenylated protein accu-
mulates in the cytosol (Supplementary Fig. 1 ‘BLOCK’). Overnight
incubation with mevastatin allows this cytosolic pool of protein
to reach a sufﬁcient concentration that it can be easily visualized
in transfected cells by confocal ﬂuorescence microscopy and does
not appear to affect cell viability. Shorter block times are also pos-
sible. Thus on release of mevastatin block and resumption of pre-
nylation, the targeting of cytosolic EGFP-GTPase fusion protein to
the membrane of intracellular organelles may be followed in
real-time by confocal ﬂuorescence microscopy providing insight
into the kinetics and mechanisms by which the newly prenylated
proteins are targeted to intracellular membranes (Supplementary
Fig. 1 ‘RELEASE’).
3.2. Prenylation block-and-release assay applied to study the targeting
of newly prenylated EGFP-Rab5a to early endosomes
As a proof of principle we applied this assay to HeLa cells tran-
siently expressing early endosome associated Rab5a [11,24]. As
shown in Fig. 1A in the absence of mevastatin treatment we ob-
served efﬁcient targeting of EGFP-Rab5a to transferrin receptor
(Tfn-R) early endosomes. In contrast mevastatin treatment of
EGFP-Rab5a expressing cells resulted in accumulation of EGFP-
Rab5a throughout the nucleus and cytoplasm (Fig. 1B, 0 min). This
pattern is similar to the distribution of EGFP alone and differs strik-
ingly from the punctate early endosome associated pattern of
EGFP-Rab5a seen in untreated cells (Fig. 1A). This is consistent
with the ability of mevastatin to prevent geranylgeranylation and
membrane targeting of newly synthesized EGFP-Rab5a. We then
released the mevastatin block and used confocal ﬂuorescence
microscopy to observe EGFP-Rab5a targeting to early endosomes.
As shown in Fig. 1B (60 min) and the Supplementary material
Fig. 1. Investigation of the membrane targeting of EGFP-Rab5a using the ‘prenylation block-and-release’ assay. HeLa cells were transfected with pEGFP-Rab5a as described
(Section 2) and then treated with drugs as described below to investigate membrane targeting of EGFP-Rab5a. (A) shows EGFP-Rab5a (left) is targeted to Tfn-R (middle)
positive early endosomes 24 h after transfection in untreated cells. Co-localization of EGFP-Rab5a (green) and Tfn-R (red) is indicated by yellow color in the right-hand panel.
(B) and (C) show images of transfected cells at indicated time-points following mevastatin (10 lM) wash-out in the absence and presence of protein synthesis inhibitor
cycloheximide, respectively. (D) conﬁrms the speciﬁcity of the mevastatin (20 lM) block on membrane targeting by showing that supplementation of cells with (GGPP
precursor) GGOH (10 lM) overcomes the effects of the prenylation inhibitor. Bars = 10 lm. (For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web version of this article.)
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served cytosolic EGFP-Rab5a re-distribute within 60 min of re-
moval of inhibitor to a punctate pattern, consistent with
targeting to early endosomes. Similar results were achieved whencells were incubated with the protein synthesis inhibitor cyclohex-
imide during the release conﬁrming that the redistribution of
EGFP-Rab5a to early endosomes results from restoration of prenyl-
ation of the accumulated pool of EGFP-Rab5a rather than targeting
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astatin blocks EGFP-Rab5a targeting to early endosome mem-
branes in transfected cells by blocking the production of GGPP
we modiﬁed the protocol so that post-transfection the membrane
permeant GGPP precursor geranylgeraniol (GGOH) was added to-
gether with mevastatin. As shown in Fig. 1D targeting of EGFP-
Rab5 to early endosomes was normal under these conditions con-
ﬁrming that mevastatin indeed blocks EGFP-Rab5a targeting by
speciﬁcally blocking GGPP production.
Overall these data indicate that the prenylation block-and-re-
lease assay may be used to study the intracellular targeting of
prenylated proteins including small GTPases. Regarding Rab5a
these data indicate that it is targeted directly from the site of pre-
nylation in the cytosol to the early endosome membrane and does
not appear to pass through an intermediate compartment as was
reported for targeting of related GTPases of the Ras and Rho fami-
lies [25,26].
3.3. Other newly prenylated Rabs are targeted directly to the organelle
on which they reside at steady-state
We next used the prenylation block-and-release assay to inves-
tigate the targeting of other Rabs to organelles of the secretory
pathway. To do this we examined the membrane targeting of
EGFP-Rab1a and EGFP-Rab27a that regulate secretory pathway ER
to Golgi transport and melanosome docking in peripheral melano-
cyte dendrites, respectively [13,27]. As for EGFP-Rab5a, we ob-
served that in the untreated cells EGFP-Rab1a and EGFP-Rab27a
were correctly targeted to the Golgi stack and mature pigmented
melanosomes in melanocytes, respectively (Fig. 2A and C). More-
over, we conﬁrm the functionality of EGFP-Rab27a as its association
with melanosomes restores their peripheral retention in Rab27a
null (melan-ash) melanocytes (Fig. 2C) [11]. Mevastatin treatment
of transfected cells resulted in a diffuse distribution of both EGFP-
Rab1a and EGFP-Rab27a throughout the nucleus and cytoplasm
consistent with the disruption of prenylation and membrane tar-
geting (Fig. 2B and C). Also in the case of EGFP-Rab27a in melan-
ash function is disrupted as evidence bymaintenance of perinuclear
clustered melanosomes in transfected cells (Fig. 2C). Subsequent
removal ofmevastatin resulted inmembrane targeting of the newly
prenylated protein. For EGFP-Rab1a protein was targeted from the
cytosol to a ribbon-like perinuclear structure, consistent with the
normal distribution of the Golgi stack, (Fig. 2B and Supplementary
Fig. 2B and Movie 2) while EGFP-Rab27a was targeted from the
cytosol to pigmented melanosomes and restored their retention
in peripheral dendrites consistent with full functionality of the tar-
geted protein (Fig. 2C). Interestingly while both Rabs targeted di-
rectly to these organelles we observed differences in the kinetics
of recovery from the block for each Rab with EGFP-Rab1a and
EGFP-Rab27a requiring 30 and 180 min, respectively. In contrast,
following release of the mevastatin block EGFP-H-Ras was ﬁrst ob-
served on the Golgi complexwithin 30 min then accumulated at the
plasma membrane at later time-points (Fig. 2D). This is consistent
with previous reports showing that H-Ras is targeted to the plasma
membrane via the classical secretory pathway [25].
3.4. Prenylation pathway inﬂuences the sensitivity to mevastatin block
and the targeting kinetics of prenylated GTPases
Finally we investigated whether the type (farnesyl versus gera-
nylgeranyl) i.e. prenylation by different prenyl transferases, or the
number of lipids (one or two) associated with a GTPase inﬂuences
sensitivity to mevastatin and the mechanism of membrane target-
ing. As mentioned above most Rabs contain two prenylatable cys-
teine residues at their extreme C-terminus and are di-
geranylgeranylated by RGGT [4]. However, a signiﬁcant numberincluding Rab23 have only one such cysteine. Also as described
in the introduction other small GTPases e.g. Rho and Ras proteins,
are singly prenylated by either GGT or FT. To address these issues
we transfected mouse pituitary derived cell line (AtT20) with
EGFP-H-Ras, EGFP-Rab23 (C-terminus tetra-peptide CSVP), pre-
dicted to be singly prenylated by FT and RGGT, respectively, and
two Rab23 mutants; EGFP-Rab23-GGCC, that may be doubly
prenylated by RGGT and EGFP-Rab23-CVLS, predicted to be a sub-
strate for FT. We then tested the mevastatin sensitivity of prenyl-
ation and cytosol to membrane targeting of each of these
proteins. As previously reported we found that all four proteins
were targeted to the plasma membrane in the absence of mevasta-
tin [25,28] (Fig. 3 untreated). Meanwhile addition of different con-
centrations of mevastatin revealed that targeting of Rab23 and
Rab23-GGCC mutant (0.1 lM mevastatin disrupts targeting) were
more sensitive to mevastatin than either Rab23-CVLS or H-Ras
(5 lM and 1.6 lM mevastatin disrupt targeting, respectively).
These data indicate that prenylation/targeting of FT substrates is
less sensitive to mevastatin than RGGT substrates. We next inves-
tigated the recovery kinetics of prenylation/membrane targeting of
GTPases that are substrates of different prenyltransferases. Consis-
tent with the higher mevastatin sensitivity of RGGT compared with
FT we found that recovery of cytosol to plasma membrane target-
ing was signiﬁcantly slower for RGGT substrates, Rab23 wild-type
and Rab23-GGCC, than for FT substrates Rab23-CVLS and H-Ras
(Fig. 4, 90 min versus 30 min, respectively).
4. Discussion
Here we established a novel prenylation block-and-release as-
say that allows direct morphological investigation of the intracel-
lular targeting of prenylated GTPases in living cells. We exploited
the ability of mevastatin to reversibly inhibit HMGCR and thus
reversibly block production of GGPP and FPP so preventing the pre-
nylation and membrane targeting of prenylated proteins. Release
of the block, on removal of the drug, allows resumption of prenyl-
ation and membrane targeting. Coupling this treatment with over-
expression of ﬂuorescently labeled protein provides a large pool of
unprenylated protein whose cytosol to membrane targeting may
then be observed on removal of the drug. Using this assay we re-
port several new ﬁndings regarding membrane targeting of Ras
family small GTPases.
Firstly, we observed that different Rabs have differing kinetics
of cytosol to membrane targeting after release of the mevastatin
block. For instance in HeLa cells Rab1a required less than 30 min
to target to the Golgi but Rab5a required 60 min to target early
endosomes while in melanocytes Rab27a required 180 min to tar-
get melanosomes. One possibly explanation for the differing rate of
targeting between different Rabs in same cell type might be that
the prenylation machinery more efﬁciently modify certain Rabs.
In support of this possibility several studies suggest that Rab27a
is less efﬁciently prenylated than other Rabs including Rab1a
[29]. Interestingly we also observed that H-Ras cytosol to plasma
membrane targeting during the release is more rapid in AtT20 than
HeLa (30 versus 120 min, respectively). Together with the differ-
ences in kinetics of targeting of Rabs in different cell types (e.g.
Rab27a in melanocytes versus Rab1a in HeLa cells) these observa-
tions suggest that rates of GGPP and FPP production as well as
expression levels of prenyltransferases may vary between these
cell types.
Secondly, of the Rabs tested we observed that all appeared to be
targeted from the cytosol directly to the membrane/organelle on
which they reside at steady-state and did not trafﬁc there via an
intermediate location. This is consistent with a previous report in
which Rab5 and Rab7 in complex with REP1 were added to strep-
tolysin-O permeabilized cells and shown to target directly to either
Fig. 2. Use of the mevastatin ‘prenylation-block-and-release assay’ to investigate the membrane targeting of EGFP-Rab1a and EGFP-Rab27a. HeLa cells and melan-ash
melanocytes were transfected with pEGFP-Rab1a or pEGFP-Rab27a, respectively, treated with mevastatin overnight before the localization of EGFP-fusion protein was
monitored during recovery from drug treatment. (A) shows EGFP-Rab1a (left) is targeted to Golgin-97 (middle) positive Golgi membranes in untreated cells. Co-localization of
EGFP-Rab1a (green) and Golgin-97 (red) is indicated by yellow in the right-hand panel. (B) shows the localization of EGFP-Rab1a in transfected cells at indicated time-points
following mevastatin (10 lM) wash-out. (C) shows the localization of EGFP-Rab27a and melanosomes (upper and lower panels, respectively) in melan-ash melanocytes in the
absence, presence or 180 min after wash-out (left, middle and right, respectively) of mevastatin (1 lM). Arrows in phase contrast images indicate transfected cells. For right-
hand panels the boxed area is enlarged and shown in the bottom right corner with arrows to indicate co-localization of EGFP-Rab27a with pigmented melanosome. (D) shows
the time-course of recovery of membrane targeting of EGFP-H-Ras in HeLa cells following wash-out of mevastatin (10 lM) (white asterisks indicate the position of the Golgi
and white arrows indicate plasma membrane associated H-Ras). Bars = 10 lm. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the
web version of this article.)
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on the targeting of Ras and Rho family GTPases which reveal that
several of these proteins are initially targeted to ER where they
are modiﬁed by Rce and Icmt before passing through classical
and non-classical secretory pathways to the plasma membrane[25,26]. Similarly we previously reported that Rab23 and other
CAAX containing Rab proteins are post-prenylation modiﬁed
in vivo by Rce1 and Icmt, resident at the ER [10]. Although the
physiological signiﬁcance of post-prenylation processing is unre-
solved this modiﬁcation may increase stability of membrane asso-
Fig. 3. Investigation of the sensitivity of different prenylation pathways to disruption by mevastatin. AtT20 cells were transiently transfected with plasmids allowing the
expression of the indicated EGFP-fusion protein, incubated overnight with the indicated concentration of mevastatin and ﬁxed before the intracellular localization of the
heterologously expressed protein was observed using confocal ﬂuorescence microscopy. Bars = 10 lm.
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taining Rabs, such as Rab23, may be initially targeted post-prenyl-
ation to the ER for processing followed by transfer to the plasma
membrane. However, in this study we found that Rab23 appears
to target directly to the plasma membrane without prior accumu-
lation on endo-membranes such as ER. One caveat to this is that
the cytosolic accumulation of unprenylated EGFP-Rab23 may ob-
scure transient localization of the protein to the ER membrane.
Thirdly, we found that GTPases that are substrates of different
prenyl transferases are differentially sensitive to mevastatin. Inparticular we found RGGT substrates are more sensitive to meva-
statin and take longer to recover from mevastatin treatment than
are FT substrates. One possible explanation for this observation is
that there might be a larger reserve of FPP and FT than GGPP
GGT in the cell. Also farnesyl is a precursor of geranylgeranyl there-
fore its synthesis is more likely to resume rapidly after the with-
drawal of mevastatin.
Fourthly, we observed using Rab23 as an example that the num-
ber of prenylatable cysteine present in the C-terminus of a GTPase
does not strongly affect its sensitivity to/or the kinetics of its recov-
Fig. 4. Investigation of the membrane targeting kinetics of GTPases that are substrates of different prenylation pathways following mevastatin wash-out. AtT20 cells were
transiently transfected with plasmids allowing the expression of the indicated EGFP-fusion protein and incubated overnight with 5 lM mevastatin. The intracellular
localization of the heterologously expressed protein was observed using confocal ﬂuorescence microscopy at the indicated time-points following mevastatin wash-out.
Bars = 10 lm.
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hood that all Rabs are prenylated via RGGT regardless of whether
they contain one or two prenylatable cysteine residues and there-
fore rate of prenylation and membrane targeting is dependent
upon the activity of the RGGT pathway.5. Conclusion
We utilized the ability of Statins to block the prenylation of pro-
teins to visualize membrane targeting of small GTPases. The assay
revealed that prenylated proteins have variable susceptibility tomevastatin inhibition and variable time of recovery indicating a
hierarchy of the picking order of the prenylated proteins. We pro-
pose that this assay may be used for further studies (e.g. targeting,
biological functions and mechanisms) of the membrane targeting
of the many the prenylated proteins.
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